Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
GLOBETECH PUBLISHING

Bee Venom Compound Tested for Radioprotector Qualities

By BiotechDaily International staff writers
Posted on 23 Jul 2012
A team of Spanish researchers conducted in vitro studies of cytotoxicity to evaluate the optimal concentration level of propolis, in which this natural substance extracted from bee resin would offer the maximum protection against ionized radiation and not be toxic for blood cells.

According to the researchers, from the Technical University of Valencia, the University Hospital La Fe, the University of Valencia, and the Universitat Autonoma de Barcelona, this optimal concentration level is between 120-500 µg/mL. “Within this range can be found maximum protection against radiation-induced damage and the substance does not reveal either a cytotoxicity nor a genotoxicity effect on nonirradiated human lymphocytes,” said Dr. Alegria Montoro, head of the laboratory of biological dosimetry at the University Hospital La Fe.

The conclusions of this study represent a starting point for future clinical applications using propolis. The results were published February 2012 in the journal Food and Chemical Toxicology, and a full revision of the study will be presented at the annual International Conference of the IEEE Engineering in Medicine and Biology Society EMBC12, which will be held in San Diego (CA, USA), in August 2012.

In the study, the researchers utilized four genetic biomarkers, including the mytotic index and the cell proliferation kinetics, with the aim of determining whether propolis has cytotoxic effects on cells. “Using these biomarkers makes it possible to discover how a substance affects cell division: a substance which is cytotoxic and modifies the cell division stage would do so by accelerating, slowing down or even stopping the process, and all three effects are negative,” explained Dr. Alegria Montoro.

The other two biomarkers used are the study of the possible induction of chromosome changesin nonirradiated cultures at different concentration levels and sister chromatid exchanges (SCEs), a genetic biomarker of exposure to chemical agents.

“With this study we already know the in vitro experimental level, the concentration of propolis to be used to make it act as a radiation protector agent, without being cyto/genotoxic for normal cells. This is the first step, a starting point for future clinical assays. The final goal is to develop capsules containing the adequate doses of propolis, but many more hours of research are needed before we are able to do this,” Dr. Alegria Montoro added.

UAB lecturer Francesc Barquinero, currently on leave to work at the Institut de Radioprotection et de Sûreté Nucléaire (IRSN; Fontenay aux Roses, France), participated in the original planning of the study and its design, as well as the interpretation of the findings and posterior contextualization of other studies published.

In 2008, researchers at the Institute for Industrial, Radiophysical and Environmental Safety (ISIRyM) of the Technical University of Valencia and the University Hospital La Fe demonstrated that propolis can reduce by half the damage inflicted on chromosomes by ionized radiations, thereby protecting the DNA from these effects. The new study is essential, according to the investigators, in finding the range of concentrations in which this compound can have a toxic effect on nonirradiated cells.

Related Links:

Technical University of Valencia
University of Valencia
University Hospital La Fe



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Differences in the structure of a small lung artery (top row) and heart cross section (lower row) of rodents without disease (far left column); with pulmonary hypertension (middle) and a diseased rodent treated with the HDL peptide (right). Note the much narrowed lung artery, and thick walls and larger chamber of the heart in the diseased animal and improvements with 4F peptide treatment (Photo courtesy of UCLA - University of California, Los Angeles).

Apolipoprotein A-1 Mimetic Peptide Reverses Pulmonary Hypertension in Rodent Models

A small peptide that mimics the activity of apolipoprotein A-1 (apo A-1), the main protein component of the high density lipoproteins (HDL), counteracted the effects of oxidized lipids and alleviated symptoms... Read more

Drug Discovery

view channel
Image: The five stages of biofilm development: (1) Initial attachment, (2) Irreversible attachment, (3) Maturation I, (4) Maturation II, and (5) Dispersion. Each stage of development in the diagram is paired with a photomicrograph of a developing P. aeruginosa biofilm. All photomicrographs are shown to same scale (Photo courtesy of Wikimedia Commons).

Ionic Liquids Disperse Bacterial Biofilms and Increase Antibiotic Susceptibility

The ionic liquid choline-geranate was shown to effectively eliminate the protective biofilm generated by bacteria such as Salmonella enterica and Pseudomonas aeruginosa and to significantly increase the... Read more

Therapeutics

view channel
Image: Hair follicle (blue) being attacked by T cells (green) (Photo courtesy of Christiano Lab/Columbia University Medical Center).

Hair Restoration Method Clones Patients’ Cells to Grow New Hair Follicles

Researchers have developed of a new hair restoration approach that uses a patient’s cells to grow new hair follicles. In addition, the [US] Food and Drugs Administration (FDA) recently approved a new drug... Read more

Lab Technologies

view channel
Image: Leica Microsystems launches the inverted research microscope platform Leica DMi8 (Photo courtesy of Leica Microsystems).

New Inverted Microscope Designed to Readily Adapt to Changing Research Demands

A new inverted microscope for biotech and other life science laboratories was designed to readily accommodate modifications and upgrades to allow it to keep current with changing research demands and interests.... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.